{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:27:35Z","timestamp":1790814455176,"version":"4.1.0"},"reference-count":65,"publisher":"Becaris Publishing Limited","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            We performed a feasibility assessment to systematically evaluate randomized controlled trials (RCTs) for generalized myasthenia gravis (gMG) treatments. The goal was to identify the advantages and disadvantages of different indirect treatment comparison (ITC) methods.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            A systematic literature review was conducted to identify relevant gMG RCTs for ITCs. The feasibility of ITCs was assessed by comparing design (including study duration and dosing schedules), population and outcome characteristics of retrieved trials, investigating network connectivity and considering appropriate ITC methods to address identified challenges.\n            <jats:bold>Results:<\/jats:bold>\n            The feasibility assessment considered 15 relevant RCTs for gMG treatments. Several barriers to conducting robust ITCs were identified, including within-trial imbalances in patient characteristics, small trial sizes and cross-trial differences in potential treatment effect modifiers (TEMs; e.g., antibody status, disease duration and prior treatment exposure). Further, heterogeneity in placebo administration characteristics and background therapies, and cross-trial variation in placebo response for key outcomes were noted. Additionally, treatment strategies (i.e., cyclical vs continuous), dosing schedules and outcome assessment timepoints were inconsistent across trials, necessitating careful consideration of methods and timepoints when interpreting outcomes. The findings suggest that ITCs anchored on placebo as a common comparator may be prone to bias, and more than one ITC approach may be necessary.\n            <jats:bold>Conclusion:<\/jats:bold>\n            ITC analyses in gMG have inherent challenges related to imbalanced treatment effect modifiers, network connectivity, varying dosing strategies and assessment timepoints. Multiple approaches to ITCs, with careful evaluation of underlying assumptions and limitations, are advised to limit bias and ensure robust comparative efficacy estimates are available to decision makers.\n          <\/jats:p>","DOI":"10.57264\/cer-2025-0009","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T09:02:19Z","timestamp":1746435739000},"source":"Crossref","is-referenced-by-count":3,"title":["Network connectivity, between-study heterogeneity and timepoint challenges in generalized myasthenia gravis: a feasibility assessment of indirect treatment comparisons"],"prefix":"10.57264","author":[{"given":"Nils Erik","family":"Gilhus","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"Department of Neurology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiju","family":"Jacob","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"},{"name":"Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hashim","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy Van","family":"Sanden","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9721-3069","authenticated-orcid":false,"given":"Christopher","family":"Drudge","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, ON L7N 3H8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Nero","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, ON L7N 3H8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Singh","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, ON L7N 3H8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson, Raritan, NJ 08869, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5662-8647","authenticated-orcid":false,"given":"Brian","family":"Hutton","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"120268","DOI":"10.1016\/j.jns.2022.120268","article-title":"The humanistic burden of myasthenia gravis: a systematic literature review","volume":"437","author":"Gelinas D","year":"2022","unstructured":"Gelinas D, Parvin-Nejad S, Phillips G The humanistic burden of myasthenia gravis: a systematic literature review. J. Neurol. Sci. 437, 120268 (2022).","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"e16233","DOI":"10.1111\/ene.16233","article-title":"The epidemiology and societal costs of myasthenia gravis in Norway: a non-interventional study using national registry data","volume":"31","author":"Engebretsen I","year":"2024","unstructured":"Engebretsen I, Gilhus NE, Kristiansen IS The epidemiology and societal costs of myasthenia gravis in Norway: a non-interventional study using national registry data. Eur. J. Neurol. 31(5), e16233 (2024).","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"e16180","DOI":"10.1111\/ene.16180","article-title":"Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy","volume":"31","author":"Sacc\u00e0 F","year":"2024","unstructured":"Sacc\u00e0 F, Salort-Campana E, Jacob S, Cort\u00e9s-Vicente E, Schneider-Gold C. Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. Eur. J. Neurol. 31(6), e16180 (2024).","journal-title":"Eur. J. Neurol."},{"issue":"7","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/03007995.2024.2353381","article-title":"Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-related events","volume":"40","author":"Zhdanava M","year":"2024","unstructured":"Zhdanava M, Pesa J, Boonmak P Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-related events. Curr. Med. Res. Opin. 40(7), 1145\u20131153 (2024).","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus NE","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat. Rev. Dis. Primers. 5(1), 30 (2019).","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"4","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders DB","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M International consensus guidance for management of myasthenia gravis. Neurology 87(4), 419\u2013425 (2016).","journal-title":"Neurology"},{"key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/ITT.S377056","article-title":"Novel immunotherapies for myasthenia gravis","volume":"12","author":"Nair SS","year":"2023","unstructured":"Nair SS, Jacob S. Novel immunotherapies for myasthenia gravis. Immunotargets Ther. 12, 25\u201345 (2023).","journal-title":"Immunotargets Ther."},{"issue":"3","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis","volume":"96","author":"Narayanaswami P","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G International consensus guidance for management of myasthenia gravis. Neurology 96(3), 114\u2013122 (2021).","journal-title":"Neurology"},{"key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","article-title":"Guideline for the management of myasthenic syndromes","volume":"16","author":"Wiendl H","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A Guideline for the management of myasthenic syndromes. Ther. Adv. Neurol. Disord. 16, 17562864231213240 (2023).","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"7","key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, Phase III trial","volume":"20","author":"Howard JF","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, Phase III trial. Lancet Neurol. 20(7), 526\u2013536 (2021).","journal-title":"Lancet Neurol."},{"issue":"5","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive Phase III study","volume":"22","author":"Bril V","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive Phase III study. Lancet Neurol. 22(5), 383\u2013394 (2023).","journal-title":"Lancet Neurol."},{"issue":"2","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a Phase III, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi C","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a Phase III, randomised, double-blind, placebo-controlled study. Lancet Neurol. 24(2), 105\u2013116 (2025).","journal-title":"Lancet Neurol."},{"issue":"12","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a Phase III, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard JF","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a Phase III, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 16(12), 976\u2013986 (2017).","journal-title":"Lancet Neurol."},{"issue":"5","key":"e_1_3_8_16_2","first-page":"EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu T","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 1(5), EVIDoa2100066 (2022).","journal-title":"NEJM Evid."},{"issue":"5","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, Phase III study","volume":"22","author":"Howard JF","year":"2023","unstructured":"Howard JF Jr, Bresch S, Genge A Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, Phase III study. Lancet Neurol. 22(5), 395\u2013406 (2023).","journal-title":"Lancet Neurol."},{"issue":"2","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti G","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res. Synth. Methods 3(2), 80\u201397 (2012).","journal-title":"Res. Synth. Methods"},{"issue":"6","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch JE","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health 15(6), 940\u2013947 (2012).","journal-title":"Value Health"},{"issue":"20","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu G","year":"2004","unstructured":"Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23(20), 3105\u20133124 (2004).","journal-title":"Stat. Med."},{"issue":"6","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher HC","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin. Epidemiol. 50(6), 683\u2013691 (1997).","journal-title":"J. Clin. Epidemiol."},{"issue":"6","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40273-015-0271-1","article-title":"Simulation and matching-based approaches for indirect comparison of treatments","volume":"33","author":"Ishak KJ","year":"2015","unstructured":"Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics 33(6), 537\u2013549 (2015).","journal-title":"Pharmacoeconomics"},{"key":"e_1_3_8_23_2","unstructured":"European Union. HTA CG Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons. (2024). Available from: https:\/\/health.ec.europa.eu\/publications\/methodological-guideline-quantitative-evidence-synthesis-direct-and-indirect-comparisons_en"},{"key":"e_1_3_8_24_2","unstructured":"Canada's Drug Agency. Reimbursement recommendation for efgartigimod alfa (Vyvgart). (2023). Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2024\/SR0782REC-Vyvgart-meta.pdf"},{"key":"e_1_3_8_25_2","unstructured":"Canada's Drug Agency. Reimbursement recommendation for ravulizumab (Ultomiris). (2023). Available from: https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2023\/SR0765Ultomiris%20-%20Confidential%20Final%20CADTH%20Recommendation%20August%2024%2C%202023%20revised.pdf"},{"key":"e_1_3_8_26_2","unstructured":"European Medicines Agency. Orphan designation withdrawal assessment report for Zilbrysq (zilucoplan). (2023). Available from: https:\/\/www.ema.europa.eu\/en\/documents\/orphan-maintenance-report\/zilbrysq-orphan-designation-withdrawal-assessment-report_en.pdf"},{"key":"e_1_3_8_27_2","article-title":"Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value","author":"Institute for Clinical and Economic Review","year":"2021","unstructured":"Institute for Clinical and Economic Review. Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value. Final Evid.Rep. (2021). Available from: https:\/\/icer.org\/assessment\/myasthenia-gravis\/","journal-title":"Final Evid.Rep."},{"key":"e_1_3_8_28_2","article-title":"Ravulizumab for treating generalised myasthenia gravis (terminated appraisal). Technology appraisal TA940","author":"National Institute for Health and Care Excellence","year":"2023","unstructured":"National Institute for Health and Care Excellence. Ravulizumab for treating generalised myasthenia gravis (terminated appraisal). Technology appraisal TA940. Com.Pap. (2023). Available from: https:\/\/www.nice.org.uk\/guidance\/ta940\/documents\/committee-papers","journal-title":"Com.Pap."},{"key":"e_1_3_8_29_2","doi-asserted-by":"crossref","first-page":"1403802","DOI":"10.3389\/fimmu.2024.1403802","article-title":"Commentary: efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis","volume":"15","author":"Zhang I","year":"2024","unstructured":"Zhang I, Jansen JP, Yungher BJ, Kielhorn A, Yee KS. Commentary: efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis. Front. Immunol. 15, 1403802 (2024).","journal-title":"Front. Immunol."},{"key":"e_1_3_8_30_2","unstructured":"Ades AE Caldwell DM Reken S Welton NJ Sutton AJ Dias S. NICE DSU Technical Support Document 7: evidence synthesis of treatment efficacy in decision making: a reviewer's checklist. (2012). Available from: https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/full-list"},{"key":"e_1_3_8_31_2","unstructured":"Dias S Sutton AJ Welton NJ Ades AE. NICE DSU Technical Support Document 3: heterogeneity: subgroups meta-regression bias and bias-adjustment. (2012). Available from: https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/full-list"},{"key":"e_1_3_8_32_2","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023)","author":"Higgins Jpt TJ","year":"2023","unstructured":"Higgins Jpt TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (Eds). Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane (2023). Available from: http:\/\/www.training.cochrane.org\/handbook"},{"issue":"4","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","article-title":"Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2","volume":"14","author":"Hoaglin DC","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP Conducting indirect-treatment-comparison and network-meta-analysis studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. Value Health 14(4), 429\u2013437 (2011).","journal-title":"Value Health"},{"key":"e_1_3_8_34_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2018-0065"},{"issue":"2","key":"e_1_3_8_35_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/bmjebm-2022-112197","article-title":"When does the placebo effect have an impact on network meta-analysis results?","volume":"29","author":"Nikolakopoulou A","year":"2024","unstructured":"Nikolakopoulou A, Chaimani A, Furukawa TA, Papakonstantinou T, R\u00fccker G, Schwarzer G. When does the placebo effect have an impact on network meta-analysis results? BMJ Evid. Based Med. 29(2), 127 (2024).","journal-title":"BMJ Evid. Based Med."},{"issue":"5","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.7326\/M15-0623","article-title":"Effectiveness and implications of alternative placebo treatments","volume":"163","author":"Bannuru RR","year":"2015","unstructured":"Bannuru RR, Mcalindon TE, Sullivan MC, Wong JB, Kent DM, Schmid CH. Effectiveness and implications of alternative placebo treatments. Ann. Intern. Med. 163(5), 365\u2013372 (2015).","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_8_37_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0021"},{"issue":"3","key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/j.pain.0000000000002365","article-title":"Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis","volume":"163","author":"Swerts DB","year":"2022","unstructured":"Swerts DB, Benedetti F, Peres MFP. Different routes of administration in chronic migraine prevention lead to different placebo responses: a meta-analysis. Pain 163(3), 415\u2013424 (2022).","journal-title":"Pain"},{"issue":"1","key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1741-7015-12-93","article-title":"A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer","volume":"12","author":"Cope S","year":"2014","unstructured":"Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 12(1), 93 (2014).","journal-title":"BMC Med."},{"key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Mckenzie JE, Bossuyt PM The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Brit. Med. J. 372, n71 (2021).","journal-title":"Brit. Med. J."},{"issue":"4","key":"e_1_3_8_41_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/mus.10224","article-title":"Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis","volume":"26","author":"Wolfe GI","year":"2002","unstructured":"Wolfe GI, Barohn RJ, Foster BM Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 26(4), 549\u2013552 (2002).","journal-title":"Muscle Nerve"},{"key":"e_1_3_8_42_2","unstructured":"European Union. HTA CG Practical Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons. (2024). Available from: https:\/\/health.ec.europa.eu\/publications\/practical-guideline-quantitative-evidence-synthesis-direct-and-indirect-comparisons_en"},{"issue":"4","key":"e_1_3_8_43_2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","article-title":"Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1","volume":"14","author":"Jansen JP","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health 14(4), 417\u2013428 (2011).","journal-title":"Value Health"},{"key":"e_1_3_8_44_2","unstructured":"Phillippo DM Ades AE Dias S Palmer S Abrams KR Welton NJ. NICE DSU Technical Support Document 18: methods for population-adjusted indirect comparisons in submission to NICE. (2016). Available from: https:\/\/www.sheffield.ac.uk\/nice-dsu\/tsds\/full-list"},{"issue":"25","key":"e_1_3_8_45_2","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin PC","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28(25), 3083\u20133107 (2009).","journal-title":"Stat. Med."},{"key":"e_1_3_8_46_2","unstructured":"ClinicalTrials.gov. Evaluating the pharmacodynamic noninferiority of efgartigimod PH20 SC administered subcutaneously as compared to efgartigimod administered intravenously in patients with generalized myasthenia gravis (ADAPT-SC). (2023). Available from: https:\/\/clinicaltrials.gov\/study\/NCT04735432"},{"issue":"23","key":"e_1_3_8_47_2","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized Phase II study of FcRn antagonist efgartigimod in generalized myasthenia gravis","volume":"92","author":"Howard JF","year":"2019","unstructured":"Howard JF, Bril V, Burns TM Randomized Phase II study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92(23), e2661\u2013e2673 (2019).","journal-title":"Neurology"},{"issue":"6","key":"e_1_3_8_48_2","doi-asserted-by":"crossref","first-page":"e853","DOI":"10.1212\/WNL.0000000000011108","article-title":"Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis","volume":"96","author":"Bril V","year":"2021","unstructured":"Bril V, Benatar M, Andersen H Efficacy and safety of rozanolixizumab in moderate to severe generalized myasthenia gravis. Neurology 96(6), e853\u2013e865 (2021).","journal-title":"Neurology"},{"issue":"5","key":"e_1_3_8_49_2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a Phase II randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard JF","year":"2020","unstructured":"Howard JF Jr, Nowak RJ, Wolfe GI Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a Phase II randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 77(5), 582\u2013592 (2020).","journal-title":"JAMA Neurol."},{"issue":"11","key":"e_1_3_8_50_2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl F","year":"2022","unstructured":"Piehl F, Eriksson-Dufva A, Budzianowska A Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 79(11), 1105\u20131112 (2022).","journal-title":"JAMA Neurol."},{"issue":"4","key":"e_1_3_8_51_2","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase II trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"98","author":"Nowak RJ","year":"2022","unstructured":"Nowak RJ, Coffey CS, Goldstein JM Phase II trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis. Neurology 98(4), e376\u2013e389 (2022).","journal-title":"Neurology"},{"key":"e_1_3_8_52_2","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of IGIV-C in symptomatic subjects with generalized myasthenia gravis. (2019). Available from: https:\/\/clinicaltrials.gov\/study\/NCT02473952"},{"issue":"7","key":"e_1_3_8_53_2","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1212\/WNL.0000000000201501","article-title":"Randomized double-blind placebo-controlled trial of the corticosteroid-sparing effects of immunoglobulin in myasthenia gravis","volume":"100","author":"Bril V","year":"2023","unstructured":"Bril V, Szczudlik A, Vaitkus A Randomized double-blind placebo-controlled trial of the corticosteroid-sparing effects of immunoglobulin in myasthenia gravis. Neurology 100(7), e671\u2013e682 (2023).","journal-title":"Neurology"},{"issue":"6","key":"e_1_3_8_54_2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/jrsm.1511","article-title":"Methods for population adjustment with limited access to individual patient data: a review and simulation study","volume":"12","author":"Remiro-Azocar A","year":"2021","unstructured":"Remiro-Azocar A, Heath A, Baio G. Methods for population adjustment with limited access to individual patient data: a review and simulation study. Res. Synth. Methods 12(6), 750\u2013775 (2021).","journal-title":"Res. Synth. Methods"},{"issue":"9","key":"e_1_3_8_55_2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jval.2024.05.015","article-title":"A targeted review of worldwide indirect treatment comparison (ITC) guidelines and best practices","volume":"27","author":"Tanaka S","year":"2024","unstructured":"Tanaka S, Igarashi A, De Moor R A targeted review of worldwide indirect treatment comparison (ITC) guidelines and best practices. Value Health 27(9), 1179\u20131190 (2024).","journal-title":"Value Health"},{"key":"e_1_3_8_56_2","article-title":"Efgartigimod for treating generalised myasthenia gravis (in development). Technology appraisal ID4003","author":"National Institute for Health and Care Excellence","year":"2023","unstructured":"National Institute for Health and Care Excellence. Efgartigimod for treating generalised myasthenia gravis (in development). Technology appraisal ID4003. Com.Pap. (2023). Available from: https:\/\/www.nice.org.uk\/guidance\/gid-ta10986\/documents\/committee-papers","journal-title":"Com.Pap."},{"key":"e_1_3_8_57_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0046"},{"issue":"2","key":"e_1_3_8_58_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(24)00514-3","article-title":"Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled Phase III trial","volume":"24","author":"Habib AA","year":"2025","unstructured":"Habib AA, Zhao C, Aban I Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled Phase III trial. Lancet Neurol. 24(2), 117\u2013127 (2025).","journal-title":"Lancet Neurol."},{"key":"e_1_3_8_59_2","unstructured":"Amgen. Amgen presents positive Phase IIIdata for Uplizna (inebilizumab-cdon) in generalized myasthenia gravis (gMG) at AANEM 2024. (2024). Available from: https:\/\/www.amgen.com\/newsroom\/press-releases\/2024\/10\/amgen-presents-positive-phase-3-data-for-uplizna-inebilizumabcdon-in-generalized-myasthenia-gravis-gmg-at-aanem-2024"},{"issue":"1","key":"e_1_3_8_60_2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1080\/13696998.2024.2334160","article-title":"Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression","volume":"27","author":"Meltzer-Brody S","year":"2024","unstructured":"Meltzer-Brody S, Gerbasi ME, Mak C Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression. J. Med. Econ. 27(1), 582\u2013595 (2024).","journal-title":"J. Med. Econ."},{"issue":"10","key":"e_1_3_8_61_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40263-017-0462-8","article-title":"Can matching-adjusted indirect comparison methods mitigate placebo response differences among patient populations in adjunctive trials of brivaracetam and levetiracetam?","volume":"31","author":"Swallow E","year":"2017","unstructured":"Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S. Can matching-adjusted indirect comparison methods mitigate placebo response differences among patient populations in adjunctive trials of brivaracetam and levetiracetam? CNS Drugs 31(10), 899\u2013910 (2017).","journal-title":"CNS Drugs"},{"key":"e_1_3_8_62_2","doi-asserted-by":"crossref","first-page":"1280226","DOI":"10.3389\/fimmu.2023.1280226","article-title":"Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis","volume":"14","author":"Chen H","year":"2023","unstructured":"Chen H, Qiu Y, Yin Z Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis. Front. Immunol. 14, 1280226 (2023).","journal-title":"Front. Immunol."},{"issue":"2","key":"e_1_3_8_63_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","article-title":"The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta-analysis","volume":"38","author":"Ma Y","year":"2024","unstructured":"Ma Y, Nie X, Zhu G, Qi W, Hao L, Guo X. The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta-analysis. CNS Drugs 38(2), 93\u2013104 (2024).","journal-title":"CNS Drugs"},{"issue":"12","key":"e_1_3_8_64_2","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1111\/ene.15872","article-title":"Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis","volume":"30","author":"Sacc\u00e0 F","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE, Sormani MP, Signori A. Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur. J. Neurol. 30(12), 3854\u20133867 (2023).","journal-title":"Eur. J. Neurol."},{"key":"e_1_3_8_65_2","doi-asserted-by":"crossref","first-page":"790834","DOI":"10.3389\/fphar.2021.790834","article-title":"Different monoclonal antibodies in myasthenia gravis: a Bayesian network meta-analysis","volume":"12","author":"Song Z","year":"2022","unstructured":"Song Z, Zhang J, Meng J Different monoclonal antibodies in myasthenia gravis: a Bayesian network meta-analysis. Front. Pharmacol. 12, 790834 (2022).","journal-title":"Front. Pharmacol."},{"issue":"12","key":"e_1_3_8_66_2","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.jval.2022.09.201","article-title":"An indirect comparison of efgartigimod versus rituximab for generalized myasthenia gravis (abstract CO123)","volume":"25","author":"Celico L","year":"2022","unstructured":"Celico L, Spaepen E, De Francesco M, Iannazzo S. An indirect comparison of efgartigimod versus rituximab for generalized myasthenia gravis (abstract CO123). Value Health 25(12), S42 (2022).","journal-title":"Value Health"},{"key":"e_1_3_8_67_2","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1007\/s12325-024-02856-3","article-title":"Efgartigimod and ravulizumab for treating acetylcholine receptor auto-antibody-positive (AChR-Ab+) generalized myasthenia gravis: indirect treatment comparison","volume":"41","author":"Van Steen C","year":"2024","unstructured":"Van Steen C, Celico L, Spaepen E Efgartigimod and ravulizumab for treating acetylcholine receptor auto-antibody-positive (AChR-Ab+) generalized myasthenia gravis: indirect treatment comparison. Adv. Ther. 41, 2486\u20132499 (2024).","journal-title":"Adv. Ther."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T09:02:33Z","timestamp":1746435753000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":65,"alternative-id":["10.57264\/cer-2025-0009"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0009","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"article-number":"e250009"}}